(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 22.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.17%.
Candel Therapeutics's earnings in 2025 is -$39,577,000.On average, 2 Wall Street analysts forecast CADL's earnings for 2025 to be -$46,094,465, with the lowest CADL earnings forecast at -$65,634,509, and the highest CADL earnings forecast at -$26,554,420.
In 2026, CADL is forecast to generate -$31,063,661 in earnings, with the lowest earnings forecast at -$31,063,661 and the highest earnings forecast at -$31,063,661.